You are here
Articles on Targeted Therapy in Gastric Cancer
This section of the Advances in Gastrointestinal Cancer Resource Centre focuses on the latest clinically relevant findings in targeted therapy for gastrointestinal cancers. The peer-reviewed articles available here have been independently selected, and several commented upon, by members of the Editorial Board. Many of the articles are freely available for downloading.
Focusing initially on gastric cancer, these pages will provide new content each month to help you stay abreast of recent scientific developments in this area.
Exciting findings from genomic sequencing have opened up the therapeutic possibilities for gastric cancer, particularly that in advanced stages, and made targeted therapy possible. Molecular signatures that appear to be associated with a poor prognosis or aggressive disease and may be amenable to targeting in gastric cancer include HER-2, EGFR, VEGF, HGF and the MET pathway, and mTOR.1
Targeted therapies already approved in the USA and Europe for use in gastric cancer include trastuzumab (which targets HER-2) and ramucirumab (which targets VEGF). Many others have been or continue to be under study in clinical trials, including the HER-2 inhibitors lapatinib and pertuzumab, the EGFR inhibitor panitumumab, the VEGF inhibitors apatinib and aflibercept. Much of the research in this area is examining combinations of these targeted agents with each other or with chemotherapy.
To stay abreast of the most recent developments and clinical trial findings in the use of targeted therapy for the treatment of gastrointestinal cancers, please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2; HGF, hepatocyte growth factor; mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor.
1. Qiu M-Z, Xu R-H. The progress of targeted therapy in advanced gastric cancer. Biomarker Res. 2013;1:32.
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
Sook Ryun Park, Young Soo Park, Min-Hee Ryu, Baek-Yeol Ryoo, Chang Gok Woo, Hwoon-Yong Jung, Jeong Hoon Lee, Gin Hyug Lee, Yoon-Koo Kang
European Journal of Cancer, January 2016, Pages 42 - 50
Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery
Findlay JM, Gillies RS, Franklin JM, Teoh EJ, Jones GE, di Carlo S, et al.Eur Radiol. 2016 Feb 16. [Epub ahead of print]
Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer
Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, et al.Gastric Cancer. 2016 Feb 13. [Epub ahead of print]
Ilson DH.J Clin Oncol. 2016 Feb 16. [Epub ahead of print]
Giandomenico Roviello, Andrea Ravelli, Karol Polom, Roberto Petrioli, Luigi Marano, Daniele Marrelli, Franco Roviello, Daniele Generali
Cancer Letters, Volume 372, Issue 2, March 2016, Pages 187 - 191
Quality-of-life and performance status results from the phase 3 RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
Al-Batran SE, Van Cutsem E, Cheul Oh S, Bodoky G, Shimada Y, Hironaka S, et al.Ann Oncol. 2016 Jan 7 [Epub ahead of print]
Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)
Saito M, Yamashita K, Arimura Y, Kaneto H, Okuda H, Nojima M, et al.Acta Oncol. 2016 Jan 12:1-9. [Epub ahead of print]
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, et al.Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408.
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al.Gastric Cancer. 2015 Oct 28. [Epub ahead of print]
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, Michael Pohl, Peter Thuss-Patience, Florian Bassermann, Ulrike Helbig, Florian Weißinger, Elisabeth Schnoy, Klaus Becker, Gertraud Stocker, Josef Rüschoff, Andreas Eisenmenger, Irini Karapanagiotou-Schenkel, Florian Lordick
European Journal of Cancer, Volume 51, Issue 5, March 2015, Pages 569 - 576